SR
Sree Raghavendra Kumar Thamada
About Sree Raghavendra Kumar Thamada
Data last updated:
Sree Raghavendra Kumar Thamada is a Director at Accore Pharmaceuticals Private Limited (since 2019). The companies operate in Trading and Construction. Accore Pharmaceuticals Private Limited reported revenue of ₹14 Lakh (FY 2022). Earlier, Sree Raghavendra Kumar Thamada was a Director at Arka Infra Projects Private Limited (2019–2022).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 12 Sep 2019 | 2019 | ₹14 Lakh (FY 2022) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 17 Sep 2019 | 2019 | Converted To Llp |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Sree Raghavendra Kumar Thamada
| Name | DIN | Company | Designation |
|---|---|---|---|
| Romala Maheswari | 10151062 | Accore Pharmaceuticals Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Sree Raghavendra Kumar Thamada
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sree Raghavendra Kumar Thamada
Sree Raghavendra Kumar Thamada currently holds 1 directorship: Accore Pharmaceuticals Private Limited (Director, since 12 Sep 2019, revenue βΉ14 Lakh (FY 2022)).
Sree Raghavendra Kumar Thamada was first appointed on 12 Sep 2019 as Director at Accore Pharmaceuticals Private Limited.
Sree Raghavendra Kumar Thamada held 1 earlier board appointment: Arka Infra Projects Private Limited (Director, 17 Sep 2019 to 09 Jan 2022).
The current boards of Sree Raghavendra Kumar Thamada's companies include Romala Maheswari (Accore Pharmaceuticals Private Limited).